Chapters

Transcript

Video

Study of SACI-IO for Triple Negative Metastatic Breast Cancer

Filipa Lynce, MD, provides an overview of a study at Dana-Farber Cancer Institute testing the safety and efficacy of sacituzumab govitecan (Trodelvy) with or without pembrolizumab (Keytruda) for patients with PD-L1-negative, triple-negative metastatic breast cancer.

Published

April 12, 2021

Created by

Dana-Farber

Related Presenters

Filipa Lynce, MD

Filipa Lynce, MD

Medical Oncology

Dr. Lynce received her medical degree from the Universidade Nova de Lisboa, Portugal in 2004.

View Profile